CETi-1. AVANT.
CETi-1, a vaccine that stimulates antibodies specific for cholesteryl ester transfer protein, is under development by AVANT Immunotherapeutics for potential use in reducing risk factors for atherosclerosis. Phase II trials with CETi-1 in hypercholesterolemia and atherosclerosis had been initiated by August 2001.
Komori
Toshihiko
T
Chugai Pharmaceutical Co Ltd, 1-9 Kyobashi 2-Chome, Chuo-Ku, Tokyo 104-8301, Japan. komoritsh@chugai-pharm.co.jp
D000818:Animals; D000924:Anticholesteremic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000276:immunology*; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters / Q000276:immunology / Q000378:metabolism; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003324:Coronary Artery Disease / Q000517:prevention & control; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology*; D006801:Humans; D013329:Structure-Activity Relationship; D014612:Vaccines / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology
D000924:Anticholesteremic Agents; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters; D006023:Glycoproteins; D014612:Vaccines